- Bay Area Times
- Posts
- Novo Nordisk wins U.S. approval for Wegovy obesity pill
Novo Nordisk wins U.S. approval for Wegovy obesity pill
Bay Area Times
December 23, 2025
Brought to you by:
Top stories today:
- Novo Nordisk wins U.S. approval for Wegovy obesity pill
- Alphabet to buy Intersect Power for $4.8B to expand AI data centers
- Larry Ellison backs Paramount’s Warner Bros. bid
- FanDuel partners with CME Group to launch prediction markets app
- ByteDance said to plan $23B in AI capex for 2026
- Erebor, Palmer Luckey’s digital bank, said to be valued at $4.4B
0. Data and calendar
All values as of 6 AM ET / 3 AM PT, other than S&P500 and NASDAQ close (4 PM ET / 1 PM PT).
All times are ET.
Listen to our AI-generated podcast summarizing today’s newsletter (beware of hallucinations):
1. Novo Nordisk wins U.S. approval for Wegovy obesity pill
Novo shares were +7.2% in early trading on Tue.:
The approval was based on results from the OASIS 4 trial.
H2 2025: Novo has also filed for approval in Europe and other regions.
Novo plans to price the 1.5mg starting dose at $149/mo. for cash-pay patients.
The insurance-covered price could be as low as $25/mo. across all doses, the company said.
The oral pill is key to Novo’s strategy to compete with Eli Lilly, which could win approval by Mar.
2. Alphabet to buy Intersect Power for $4.8B to expand AI data centers
Alphabet shares closed +1% on the announcement:
The deal includes Intersect’s power platform, team, and assets already contracted by Google.
Dec. 2024: Google backed Intersect in a funding round alongside TPG Rise Climate.
Intersect will retain its brand and CEO Sheldon Kimber.
The cash-plus-debt deal aims to secure more power for Google’s AI data centers.
Assets serving other customers will be excluded, with TPG Rise Climate retaining a stake.
We provide human cryopreservation, using extremely low temperatures to stop biological processes in the body. Patients are cryopreserved in the expectation that future technology may be able to revive them and treat their underlying cause of death.
We’ve improved all aspects of human cryopreservation, including patient storage, by building a secure long-term facility in Switzerland where patients are stored indefinitely until revival may one day be possible.
Membership includes cost savings on cryopreservation costs and access to our community and resources. Use code BAY10 for 10% off when you’re ready. Start by learning how cryopreservation actually works on our site.
*Bay Area Times partner.
